Tourmaline Bio, Inc. (TRML)
(Delayed Data from NSDQ)
$47.64 USD
+17.46 (57.85%)
Updated Sep 9, 2025 04:00 PM ET
After-Market: $47.63 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRML 47.64 +17.46(57.85%)
Will TRML be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRML based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRML
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
TRML: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TRML
Dow Surges Over 100 Points; Korn Ferry Earnings Top Views
12 Health Care Stocks Moving In Tuesday's Intraday Session
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz
Tourmaline Bio downgraded to Market Perform from Outperform at LifeSci Capital